Fosun Pharma, together with the Fosun Foundation, set up the Special Fund for Fosun Pharma Health Care Initiative,?

which implemented types of social welfare activities in the fields of health care, scientific research and innovation, and public donation, actively fulfilling the duty as an enterprise.

  • Healthcare Demonstration Project for Rural Revitalization

    On November 6, 2021, International Health Exchange and Cooperation Center NHC PRC (IHECC) and Fosun Pharma signed a strategic cooperation memorandum on the healthcare demonstration project for rural revitalization.
    In the future, the two sides will build a healthcare demonstration project for rural revitalization to enhance the capacity building of rural doctors and improve the capacity of primary healthcare services based on the actual need of the key groups such as aged people and children in rural areas. We will also explore valuable experiences that can be replicated and promoted throughout the country, so as to promote common prosperity and contribute to the construction of healthy China and rural revitalization under the new development stage. According to the memorandum, the two sides will cooperate in improving the primary healthcare service system, constructing primary healthcare talent teams, upgrading primary healthcare service capacity, and exploring innovative service models.
  • Hand in Hand- Rural Medical Talent Vitalization Plan

    In order to better assist rural vitalization, the "Fosun Care 121" Special Fund has launched the "Hand in Hand Rural Medical Talent Vitalization Plan" with the vast number of rural doctors as the target group. The plan includes "Four Ones", that is, a Pocket Book for Rural Doctors' Diagnosis and Treatment, a cloud guardian platform for rural doctors, a group of health care ambassador hand in hand assistance through online consultation, aiming to combine online and offline ways to help rural doctors master the expertise relating to diagnosis and treatment and health management, and obtain the timely and effective answers to the diagnosis and treatment.
  • Helping Africa fight malaria

    By the end of 2021, Artesun® (artesunate for injection), self-developed and manufactured by Fosun Pharma, has been used to treat over 48 million severe malaria patients worldwide by the end of 2021, which turned to be a symbol of China's self-developed innovative medicines to the world.
    In August 2018, Fosun Pharma’s SPAQ-CO® Disp (co-packed sulfadoxine-pyrimethamine dispersible tablets and amodiaquine dispersible tablets), which indicated for the prevention of malaria in children, was pre-qualified by WHO(WHO-PQ). By end of 2021, around 175 million children in high malaria transmission African countries had benefited from the "Seasonal Malaria Chemoprevention Program", for which SPAQ-CO® Disp is used as the core drug. SMC with SPAQ-CO® Disp effectively reduced the morbidity of malaria in children under five years old in Africa.
    With advantage of its product advantages, Fosun Pharma has organized 11 seminars on malaria prevention and control in developing countries, 6 seminars on quality management in developing countries, and 4 ministerial seminars on drug regulation in developing countries, in which more than 50 countries have participated.
  • Fight against COVID-19 Pandemic

    Since the outbreak of the COVID-19 pandemic in 2020, Fosun Pharma has made full use of its innovation capabilities and international experiences to actively participate in the global fight against the epidemic, with mobilization of supplies from around the world, development of COVID-19 drugs and research and development of novel coronavirus nucleic acid and antigen detection reagents. In collaboration with Germany's BioNTech to jointly develop mRNA COVID-19 vaccine, Fosun Pharma continues to help fight the COVID-19 pandemic.
    COMIRNATY® (mRNA COVID-19 vaccine) jointly developed by Fosun Pharma and BioNTech, was included in the government vaccination programs in Hong Kong SAR and Macau SAR in March 2021 and supplied to the Taiwan region in September 2021. By the end of February 2022, over 20 million doses of BNT162b2 have been administrated in Hong Kong SAR, Macau SAR, and Taiwan region, helping to establish the local COVID-19 immune barrier. Sublicensed from MPP to manufacture both drug substance and product and commercialize COVID-19 oral drugs Molnupiravir and Paxlovid in agreed low- and middle-income countries.
  • "Future Stars Program" continued to support education

    In 2021, Fosun Pharma continued to implement the “Future Star Program”, and set up scholarships and teaching assistantship in School of Life Sciences Fudan University, China Pharmaceutical University, Shenyang Pharmaceutical University, Tongji Medical College of Huazhong University of Science and Technology and Xuzhou Medical University. Over the past year, the program has motivated more than 150 excellent students and teachers, in order to encourage students excellent in character and learning to seek medical knowledge and encourage teachers to be devoted to scientific research and cultivation of social talents. The cooperation in university- enterprise scholarship deepened the communication and interaction between Fosun Pharma and universities, and the cooperation in talent cultivation and provision.
  • HAN QU YOU® Rural Healthcare Public Welfare Tour

    Henlius has launched the activity of "Excellent Medical Assistance—HAN QU YOU® Rural Healthcare Public Welfare Tour", together with the Fosun Foundation, People's Daily Health app, and Health Times of People's Daily. The program is committed to improving the medical conditions, diagnosis and treatment level, and hospital management capacity of remote villages in China, raising the awareness of more rural people on major cancer diseases such as breast cancer and realizing the dream of building a "Healthy China". A number of domestic renowned oncologists and hospital management teams will be invited to carry out public welfare training for rural doctors and villagers on the prevention, diagnosis and treatment of major cancer diseases such as breast cancer, covering more than 10 counties and towns. We will also provide consultation and free diagnosis of difficult cases, engage in the frontline of cancer prevention and treatment, and contribute to the standardized diagnosis and treatment of diseases.
  • Provided medical supplies to Henan’s disaster-stricken areas

    In July, 2021, the rainstorm in Henan caused floods, and the destruction of the infrastructure in many areas, which brought great threats to people’s lives and property. On 21 July, Fosun Foundation announced a donation of RMB50 million of funds and materials, among which, Fosun Pharma, as one of the donation units, donated a total of RMB10 million of materials and funds to help Henan, especially Zhengzhou and other areas seriously hit by floods. Materials included all-terrain amphibious vehicles, Italian mobile photographic X-ray machine equipment, COVID-19 nucleic acid reagent, Fosun healthy family medicine box, HiPee intelligent health elf urine detector and other urgently needed materials.
  • Han Da Yuan® Patient Caring Program

    To help treat more patients with autoimmune diseases, Fosun Pharma has established the first whole-process care platform in China for them, called "Dagen's Home", which incorporates internet hospitals, science popularization education, public welfare assistance, medical insurance, patient management, medicine purchase map, and community care. By the end of 2021, "Dagen's Home" had provided 1v1 special services for over 5,000 patients in total, solving their problems in consultation, diagnosis, treatment, and prognosis. Besides, it donated Mr. Li Hua, who suffered from ankylosing spondylitis (AS), all the Han Da Yuan® that he would need.
友情链接:海博测评网  海博论坛社区  鸿运国际  w88优德体育  sa36沙龙会网站  宝马bm555线路  伟德国际BETVlCTOR  ladbrokes立博  尊龙凯时人生就是搏  正点游戏